<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577537</url>
  </required_header>
  <id_info>
    <org_study_id>SPL7013-016</org_study_id>
    <nct_id>NCT01577537</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis</brief_title>
  <official_title>A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Starpharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Starpharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to
      placebo gel for the treatment of bacterial vaginosis (BV).

      After screening eligible participants will be randomized to receive either 1% SPL7013 Gel or
      hydroxyethyl cellulose (HEC) placebo gel at a dose of 5g administered vaginally at bedtime
      for 7 consecutive days. Participants will be assessed for BV (both by Amsel criteria and
      Nugent score) at screening/Baseline, after last application (End of Treatment, EOT, Day 9-12)
      and at the final study visit approximately 2-3 weeks after last dose (Test of Cure, TOC, Day
      21-30).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2012</start_date>
  <completion_date type="Actual">October 5, 2012</completion_date>
  <primary_completion_date type="Actual">October 5, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Women With Clinical Cure at the End of Treatment Visit (EOT)</measure>
    <time_frame>Day 9-12</time_frame>
    <description>Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Women With Nugent Cure at the EOT Visit</measure>
    <time_frame>Day 9-12</time_frame>
    <description>Nugent Cure is defined as a Nugent score of 0-3 (normal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Women With Clinical Cure at the Test of Cure Visit (TOC)</measure>
    <time_frame>Day 21-30</time_frame>
    <description>Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Women With Nugent Cure at the TOC Visit</measure>
    <time_frame>Day 21-30</time_frame>
    <description>Nugent Cure is defined as a Nugent score of 0-3 (normal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Potentially Related to Treatment</measure>
    <time_frame>Screening/baseline through TOC visit, Day 1-30</time_frame>
    <description>Number of participants experiencing adverse events considered potentially related to study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>VivaGel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HEC Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% SPL7013 Gel</intervention_name>
    <description>Vaginal gel, daily for 7 days</description>
    <arm_group_label>VivaGel</arm_group_label>
    <other_name>VivaGel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaginal gel, daily for 7 days</description>
    <arm_group_label>HEC Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key eligibility criteria:

          -  Post-menarchal females, aged 12 years or more

          -  Diagnosis of BV by Amsel criteria (ie all four of the following signs/symptoms:
             presence of white to grey homogeneous discharge; positive whiff test indicating an
             amine (fishy) odor with addition of potassium hydroxide; vaginal pH greater than 4.5;
             and presence at least 20% clue cells of total epithelial cells

          -  Nugent score of at least 4

          -  Otherwise healthy, as determined by medical history, physical examination

          -  normal Pap smear at or documented within 24 months of screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Paull, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Starpharma Pty Ltd</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <results_first_submitted>April 29, 2019</results_first_submitted>
  <results_first_submitted_qc>June 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2019</results_first_posted>
  <disposition_first_submitted>October 17, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 25, 2012</disposition_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPL7013</keyword>
  <keyword>VivaGel</keyword>
  <keyword>bacterial vaginosis</keyword>
  <keyword>BV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VivaGel</title>
          <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
        </group>
        <group group_id="P2">
          <title>HEC Placebo</title>
          <description>Placebo: Vaginal gel, daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>modified intent-to-treat (mITT) population, which included all participants in the Safety population who had a Nugent score of 4-10 at Baseline, but excluded those with a Nugent score of 0-3.</population>
      <group_list>
        <group group_id="B1">
          <title>VivaGel</title>
          <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
        </group>
        <group group_id="B2">
          <title>HEC Placebo</title>
          <description>Placebo: Vaginal gel, daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="237"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9" spread="9.9"/>
                    <measurement group_id="B2" value="36.2" spread="12.3"/>
                    <measurement group_id="B3" value="35.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Women With Clinical Cure at the End of Treatment Visit (EOT)</title>
        <description>Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)</description>
        <time_frame>Day 9-12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>VivaGel</title>
            <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>HEC Placebo</title>
            <description>Placebo: Vaginal gel, daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women With Clinical Cure at the End of Treatment Visit (EOT)</title>
          <description>Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Women With Nugent Cure at the EOT Visit</title>
        <description>Nugent Cure is defined as a Nugent score of 0-3 (normal)</description>
        <time_frame>Day 9-12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>VivaGel</title>
            <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>HEC Placebo</title>
            <description>Placebo: Vaginal gel, daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women With Nugent Cure at the EOT Visit</title>
          <description>Nugent Cure is defined as a Nugent score of 0-3 (normal)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Women With Clinical Cure at the Test of Cure Visit (TOC)</title>
        <description>Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)</description>
        <time_frame>Day 21-30</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>VivaGel</title>
            <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>HEC Placebo</title>
            <description>Placebo: Vaginal gel, daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women With Clinical Cure at the Test of Cure Visit (TOC)</title>
          <description>Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Women With Nugent Cure at the TOC Visit</title>
        <description>Nugent Cure is defined as a Nugent score of 0-3 (normal)</description>
        <time_frame>Day 21-30</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>VivaGel</title>
            <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>HEC Placebo</title>
            <description>Placebo: Vaginal gel, daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women With Nugent Cure at the TOC Visit</title>
          <description>Nugent Cure is defined as a Nugent score of 0-3 (normal)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Potentially Related to Treatment</title>
        <description>Number of participants experiencing adverse events considered potentially related to study treatment.</description>
        <time_frame>Screening/baseline through TOC visit, Day 1-30</time_frame>
        <population>Safety population. Two participants of those randomized to the 1% SPL7013 Gel group withdrew consent, did not use study medication, and therefore were not included in the Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>VivaGel</title>
            <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>HEC Placebo</title>
            <description>Placebo: Vaginal gel, daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Potentially Related to Treatment</title>
          <description>Number of participants experiencing adverse events considered potentially related to study treatment.</description>
          <population>Safety population. Two participants of those randomized to the 1% SPL7013 Gel group withdrew consent, did not use study medication, and therefore were not included in the Safety population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Analysis of all participants who received (were dispensed) the study medication, excluding any participants who returned all the study medication unused (Safety population). This population is broader than the modified intent-to-treat population, which included all participants in the Safety population who had a Nugent score of 4-10 at Baseline, but excluded those with a Nugent score of 0-3.</desc>
      <group_list>
        <group group_id="E1">
          <title>VivaGel</title>
          <description>1% SPL7013 Gel: Vaginal gel, daily for 7 days</description>
        </group>
        <group group_id="E2">
          <title>HEC Placebo</title>
          <description>Placebo: Vaginal gel, daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For multicenter studies, PIs can publish only after data from all sites are published collectively.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Jeremy Paull</name_or_title>
      <organization>Starpharma</organization>
      <email>jeremy.paull@starpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

